What was known before {#section22-2054358119887154}
=====================

Prior to this review, it was known that chronic kidney disease is a significant health care burden which disproportionately affects both indigenous populations and individuals living in remote regions. This has made the field a growing area of intervention and study, with telehealth and satellite dialysis programs growing to provide care to this area. Although there have been multiple studies of interventions targeting remote populations, these have not been previously reviewed for a global assessment of what interventions work.

What this adds {#section23-2054358119887154}
==============

This review highlights the range of interventions in this area, including multidisciplinary trials targeting non-dialysis-dependent chronic kidney disease, telehealth, and satellite programs. These interventions tend to show improvements in clinical outcomes such as blood pressure. Telehealth and satellite programs are associated with increased patient satisfaction and decreased travel time. Indigenous populations warrant particular focus in this field and interventions in this area must be both clinically effective and culturally safe.

Introduction {#section24-2054358119887154}
============

Chronic kidney disease (CKD) is a significant health care burden, affecting almost 3 million Canadians and 1 in 10 people worldwide.^[@bibr1-2054358119887154]^ Chronic kidney disease occurs more commonly and with earlier onset in indigenous communities in developed nations such as Canada, New Zealand, and Australia.^[@bibr2-2054358119887154][@bibr3-2054358119887154]-[@bibr4-2054358119887154]^ This is likely related to low socioeconomic status and remote location.^[@bibr5-2054358119887154],[@bibr6-2054358119887154]^ Among indigenous and non-indigenous patients, there is an association between remote location and increased rates of CKD; these populations are less likely to receive optimal care and monitoring and more likely to have higher mortality.^[@bibr7-2054358119887154],[@bibr8-2054358119887154]^

Remote and indigenous communities bear a disproportionate burden due to multiple socioeconomic factors, leading to higher rates of hypertension, diabetes, and their sequelae.^[@bibr6-2054358119887154],[@bibr9-2054358119887154]^ They also face decreased access to care due to travel distances, lack of regular access to a nephrologist, and lack of a culturally safe health care infrastructure.^[@bibr10-2054358119887154]^

Given the disproportionate burden of CKD in remote and indigenous communities, the inferior clinical outcomes, and the unique barriers in overcoming this burden, it is imperative to identify interventions that enhance clinical outcomes in these populations. This is the first scoping review describing interventions to enhance CKD-related clinical outcomes, along the patient experience spectrum from early CKD to provision of renal replacement therapy, in remote and indigenous communities within developed nations.

Materials and Methods {#section25-2054358119887154}
=====================

Search Strategy and Study Selection Criteria {#section26-2054358119887154}
--------------------------------------------

A scoping review was conducted using Cochrane, Embase, and MEDLINE databases, with no date restriction, using English only. Search terms included "nephrology," "kidney disease," "rural population," "rural health," "medically underserviced area," "health services accessibility," "aboriginal," "indigenous," "rural," "remote," "low-resource," and "underserved." Conference abstracts were searched from annual meetings of nephrology (American Society of Nephrology 2003-2018, Canadian Society of Nephrology 2012-2018, European Dialysis and Transplant Association 2002-2018, and Australia New Zealand Society of Nephrology 1998-2018). Search terms for conference abstracts were "rural," "remote," "indigenous," and "low-resource."

Studies were included if the study location was in a country ranked high or very high on the United Nations Development Programme Human Development Index.^[@bibr11-2054358119887154]^ Cases that were referenced in articles, but not found in the primary search, were hand searched and collected. Initial studies for screening were extracted by N.O. Both authors independently reviewed all abstracts to extract articles for full review.

Studies were included if they were intervention-based trials that measured clinical renal outcomes in patients with CKD. Clinical renal outcomes included progression to dialysis, death due to renal disease, and CKD-related laboratory measures (creatinine, estimated glomerular filtration rate \[eGFR\], Ca-P product, Kt/V, and albumin). Patient quality of life (QOL) and satisfaction were secondary, non-clinical outcomes that were also included as valid outcomes for this study. Multidisciplinary studies were any that included non-physician providers giving delegated care (eg, nurses, nurse practitioners, dieticians, and community health workers). Studies that evaluated cost as an outcome were also included. Screening studies were excluded unless they evaluated an intervention to modify a CKD-related outcome. Both authors independently reviewed all manuscripts and discrepancies were discussed to reach consensus on article inclusion.

Data Synthesis and Analysis {#section27-2054358119887154}
---------------------------

All studies were described by study type, intervention, and clinical outcome. Study characteristics of interest included study design, country, population studied (indigenous vs non-indigenous, hemodialysis \[HD\] vs peritoneal dialysis \[PD\] vs CKD not on dialysis). Intervention characteristics recorded included intervention type. Clinical outcome characteristics included the type of clinical outcome measured, and the effect the intervention had on the clinical outcome. Blood pressure was not considered a renal outcome unless the study population had kidney disease.

Meta-analysis of data was not possible because of the heterogeneous nature of available studies.

Ethics {#section28-2054358119887154}
------

Ethics approval was not required for this type of study as it included only previously collected data.

Results {#section29-2054358119887154}
=======

Search of MEDLINE, Embase, and Cochrane databases yielded 661 references ([Figure 1](#fig1-2054358119887154){ref-type="fig"}). These were screened and duplicates removed to yield 59 manuscripts. Additional 23 references were added by hand searching and reviewing references, leaving 82 manuscripts for review. There were 26 studies that met criteria for inclusion in the review. Review of conference proceedings yielded 15 additional studies. Duplicates and screening studies were excluded, yielding 32 unique studies for inclusion in this review.

![PRISMA flow diagram for scoping review.](10.1177_2054358119887154-fig1){#fig1-2054358119887154}

Study Characteristics {#section30-2054358119887154}
---------------------

The most common study design was cohort (15/32, 46.9%; [Table 1](#table1-2054358119887154){ref-type="table"}), with prospective cohort studies being the most common (12/32, 37.5%). A minority of studies (2/32, 6.3%) were randomized controlled trials. There were equal numbers of observational (6/32, 18.8%) and survey (6/32, 18.8%) studies.

###### 

Study Characteristics.

![](10.1177_2054358119887154-table1)

  Study characteristics          N (%)
  ------------------------------ -----------
  Type                           
   Randomized controlled trial   2 (6.3)
   Cohort (prospective)          12 (37.5)
   Cohort (cross-sectional)      2 (6.3)
   Cohort (retrospective)        1 (3.1)
   Descriptive (observational)   6 (18.8)
   Descriptive (survey)          6 (18.8)
   Cost-effectiveness model      1 (3.1)
   Other                         1 (3.1)
  Country                        
   Australia                     9 (28.1)
   Canada                        9 (28.1)
   New Zealand                   3 (9.4)
   United States                 3 (9.4)
   United Kingdom                3 (9.4)
   Norway                        1 (3.1)
   Jordan                        1 (3.1)
   Thailand                      1 (3.1)
   France                        1 (3.1)
  Population                     
   Indigenous persons            11 (34.4)
   CKD (non-dialysis)            16 (50.0)
   Hemodialysis                  15 (46.9)
   Acute hemodialysis            1 (3.1)
   Peritoneal dialysis           1 (3.1)
  Intervention                   
   Multidisciplinary             11 (34.4)
   Telehealth                    10 (32.3)
   Satellite clinic              8 (25.0)
   Other                         3 (9.4)

*Note.* CKD = chronic kidney disease.

Equivalent numbers of studies were performed in Australia and Canada (9/32, 28.1% for both), and in New Zealand, United States, and United Kingdom (3/32, 9.4% for each). Indigenous persons were the study population in 11 (34.4%) of studies. Half of the studies targeted CKD (non-dialysis patients). Only 1 study (3.1%) looked at outcomes in PD patients, and only 1 study (3.1%) evaluated outcomes in patients affected by HD-dependent acute kidney injury (AKI).

The greatest proportion of studies (34.4%) evaluated multidisciplinary interventions, whereas telehealth (32.3%) and satellite clinics (25.0%) made up most remaining studies. All satellite clinic intervention studies examined outcomes in HD patients, whereas all multidisciplinary intervention studies examined outcomes in CKD patients. The single study performed in PD patients was a telehealth intervention.

Outcome Characteristics {#section31-2054358119887154}
-----------------------

The most common clinical outcome measured was improvement in blood pressure (10/32, 31.3%) and was usually (8/10) measured by multidisciplinary intervention, such that it was the most common clinical outcome assessed in these studies. Death was infrequently evaluated (4/32, 12.5%). Incidence of end-stage renal disease (ESRD) was measured in 2 (6.3%) studies, both of which were multidisciplinary interventions ([Table 2](#table2-2054358119887154){ref-type="table"}).

###### 

Outcome Characteristics.

![](10.1177_2054358119887154-table2)

                                          End point                 Study type   Total (n = 32)                            
  --------------------------------------- ------------------------- ------------ ---------------- ----------- ------------ ------------
  Clinical events                         Improved blood pressure   8 (72.7%)    1 (10.0%)        1 (12.5%)   0 (0.0%)     10 (31.3%)
  Medication prescription                 4 (36.4%)                 1 (10.0%)    0 (0.0%)         0 (0.0%)    5 (15.6%)    
  Death                                   3 (27.3%)                 0 (0.0%)     1 (12.5%)        0 (0.0%)    4 (12.5%)    
  Hospitalization                         0 (0.0%)                  2 (20.0%)    1 (12.5%)        0 (0.0%)    3 (9.4%)     
  ESRD                                    2 (18.2%)                 0 (0.0%)     0 (0.0%)         0 (0.0%)    2 (6.3%)     
  Composite (2 x Cr, eGFR and/or death)   0 (0.0%)                  1 (10.0%)    0 (0.0%)         0 (0.0%)    1 (3.1%)     
  Other                                   0 (0.0%)                  1 (10.0%)    1 (12.5%)        0 (0.0%)    2 (6.3%)     
  Lab Investigations                      Proteinuria               7 (64.6%)    0 (0.0%)         0 (0.0%)    0 (0.0%)     7 (21.9%)
  Serum creatinine or eGFR                5 (45.5%)                 1 (10.0%)    0 (0.0%)         1 (33.3%)   7 (21.9%)    
  Dialysis clearance (Kt/V or URR)        0 (0.0%)                  2 (20.0%)    3 (37.5%)        0 (0.0%)    5 (15.6%)    
  Other                                   7 (63.6%)                 2 (20.0%)    3 (37.5%)        1 (33.3%)   13 (40.6%)   
  Patient related                         QOL                       2 (18.2%)    5 (50.0%)        4 (50.0%)   1 (33.3%)    12 (7.5%)
  Travel time or distance                 2 (18.2%)                 2 (20.0%)    2 (25.0%)        1 (33.3%)   7 (21.9%)    
  Cost                                    0 (0.0%)                  1 (10.0%)    2 (25.0%)        0 (0.0%)    3 (9.4%)     
  Other                                   1 (9.1%)                  3 (30.0%)    0 (0.0%)         0 (0.0%)    4 (12.5%)    
  Provider related                        Satisfaction              1 (9.1%)     5 (50.0%)        0 (0.0%)    0 (0.0%)     6 (18.8%)
  Travel time or distance                 0 (0.0%)                  1 (10.0%)    0 (0.0%)         0 (0.0%)    1 (3.1%)     
  Cost                                    0 (0.0%)                  1 (10.0%)    0 (0.0%)         0 (0.0%)    1 (3.1%)     
  Number of on-site visits                0 (0.0%)                  1 (10.0%)    0 (0.0%)         0 (0.0%)    1 (3.1%)     
  Program specific                        Cost                      1 (9.1%)     2 (20.0%)        0 (0.0%)    1 (33.3%)    4 (12.5%)

*Note.* Cr = creatinine; ESRD = end-stage renal disease; eGFR = estimated glomerular filtration rate; QOL = quality of life; Kt/V = dialysis clearance (single pool or weekly); URR = urea reduction ratio.

The most common lab investigations measured were proteinuria (7/32, 21.9%) and serum creatinine/eGFR (7/32, 21.9%); these were measured with multidisciplinary interventions in CKD patients. Hemodialysis clearance was an outcome in 5 studies (15.6% total, 33.3% HD studies), 2 of which were telehealth and 3 of which were satellite HD studies.

Patient-centered secondary outcomes of interest were also included in this review. These included QOL, satisfaction, costs, and travel time. Patient QOL (12/32, 37.5%) and travel time or distance (7/32, 21.9%) were evaluated at least once in each study type. Patient-associated costs were rarely considered (3/32, 9.4%).

The most commonly described provider-related outcome was satisfaction with the intervention (6/32, 18.8%), most often (5/6) in telehealth settings. Program-specific costs were reported in 4 (12.5%) studies.

Description of Outcomes: Multidisciplinary {#section32-2054358119887154}
------------------------------------------

Multidisciplinary studies were any which included non-physician providers giving delegated care (such as nurses, nurse practitioners, dieticians, and community health workers). All multidisciplinary interventions were implemented in the CKD setting,^[@bibr8-2054358119887154],[@bibr12-2054358119887154][@bibr13-2054358119887154][@bibr14-2054358119887154][@bibr15-2054358119887154][@bibr16-2054358119887154][@bibr17-2054358119887154][@bibr18-2054358119887154][@bibr19-2054358119887154][@bibr20-2054358119887154][@bibr21-2054358119887154]-[@bibr22-2054358119887154]^ with most (9/11, 81.8%) evaluating indigenous populations ([Appendix](#app1-2054358119887154){ref-type="app"} [Table A1](#table3-2054358119887154){ref-type="table"}).^[@bibr8-2054358119887154],[@bibr12-2054358119887154][@bibr13-2054358119887154][@bibr14-2054358119887154][@bibr15-2054358119887154]-[@bibr16-2054358119887154],[@bibr18-2054358119887154][@bibr19-2054358119887154][@bibr20-2054358119887154]-[@bibr21-2054358119887154]^ All studies utilizing multidisciplinary interventions for indigenous persons were performed in Australia, New Zealand, or Canada.^[@bibr18-2054358119887154]^

Components of multidisciplinary interventions were diverse. Specialist consultation was often led in the community by non-MD health professionals.^[@bibr12-2054358119887154][@bibr13-2054358119887154][@bibr14-2054358119887154][@bibr15-2054358119887154][@bibr16-2054358119887154][@bibr17-2054358119887154]-[@bibr18-2054358119887154]^ These clinics may have also included home visits,^[@bibr17-2054358119887154]^ transportation of patients to pharmacy and lab,^[@bibr13-2054358119887154]^ or counseling about lifestyle choices.^[@bibr14-2054358119887154][@bibr15-2054358119887154][@bibr16-2054358119887154]-[@bibr17-2054358119887154]^

Nephrology MD specialists were used to advise via telehealth,^[@bibr12-2054358119887154]^ to travel to multidisciplinary remote clinics,^[@bibr21-2054358119887154]^ or to suggest medication adjustments.^[@bibr13-2054358119887154]^ One trial used a team that included a primary care provider MD, nurse practitioner, and diabetes specialist; this team modified antihypertensive therapy, made home visits, and provided culturally appropriate care regarding lifestyle and diet, to an indigenous population.^[@bibr19-2054358119887154]^

Multidisciplinary interventions showed significant improvements in consultation waiting time,^[@bibr22-2054358119887154]^ patient travel time,^[@bibr21-2054358119887154]^ and cost.^[@bibr22-2054358119887154]^ Program cost savings were in travel costs for providers. Satisfaction among staff and patients is high.^[@bibr8-2054358119887154],[@bibr12-2054358119887154],[@bibr18-2054358119887154],[@bibr20-2054358119887154]^

Kidney function (eGFR or serum creatinine) regressed less,^[@bibr17-2054358119887154],[@bibr19-2054358119887154]^ with decreased renal death.^[@bibr16-2054358119887154]^ Proteinuria was either unchanged^[@bibr17-2054358119887154]^ or improved.^[@bibr15-2054358119887154],[@bibr16-2054358119887154],[@bibr19-2054358119887154]^ Kidney function was reported as an improvement in eGFR from before to after intervention^[@bibr19-2054358119887154]^ or change in eGFR over time compared between intervention and control groups.^[@bibr17-2054358119887154]^ Blood pressure was significantly improved.^[@bibr8-2054358119887154],[@bibr14-2054358119887154],[@bibr17-2054358119887154],[@bibr19-2054358119887154],[@bibr20-2054358119887154]^ However, improvement in blood pressure was more challenging as CKD progressed.^[@bibr18-2054358119887154]^ Follow-up was longer than 12 months in only 1 study;^[@bibr15-2054358119887154],[@bibr16-2054358119887154]^ after 3 years of intervention, the community health workers clinic handed over to local community workers. This transition was followed by increased blood pressure, renal death, and overall death.

Mortality was assessed in 2 studies. Researchers used a cluster randomized controlled trial in Thailand to assess the impact of a community-based multidisciplinary team on a composite end point of mortality, cardiac events, ESRD, and 50% increase in serum creatinine.^[@bibr17-2054358119887154]^ Although none of the individual components reached statistical significance, there was a 42% reduction in the composite end point in the intervention arm.

Hoy et al^[@bibr15-2054358119887154],[@bibr16-2054358119887154]^ conducted the longest multidisciplinary intervention study that evaluated mortality. This 3.5-year study was conducted between 1995 and 1998, with subsequent follow-up in 2003 after handover of the initiative to a remote, Indigenous community in Australia. Systematic titration of medications for blood pressure and diabetes management was combined with risk factor counseling and follow-up with allied health professionals. Nephrologists were involved remotely for consultation. The study showed a 50% reduction in all-cause mortality and 57% reduction in renal deaths over the first study period from 1995 to 1998. However, following project handover to the community, clinical gains declined over time, with increased rates of renal death and overall death. The decline in outcomes may have been due to funding and rapid staff turnover.

Description of Outcomes: Telehealth {#section33-2054358119887154}
-----------------------------------

Telehealth involved a computerized link from a main central nephrology site to a remote unit with a camera and sound activated. In all studies, the patient was at the remote site with an assistant (health care worker), with clinical and physical exam information communicated to a nephrology specialist at the central site. Physical examination was accentuated in 1 study that evaluated PD patients, with Bluetooth-connected stethoscopes and cameras directed to the patient's PD catheter exit site ([Appendix](#app1-2054358119887154){ref-type="app"} [Table A2](#table4-2054358119887154){ref-type="table"}).^[@bibr23-2054358119887154]^

Different telehealth HD models (standard virtual patient rounds vs telecase reviews with multidisciplinary teams) were compared in 1 study, showing no difference in the number of HD sessions, medication changes, or transfers to main hospital per month.^[@bibr24-2054358119887154]^

Remote patients on PD were targeted in only 1 study, in which in-person appointments at the main center were followed by telemedicine clinics thereafter. The telemedicine intervention associated with longer physician encounters, but patients' driving time was reduced and QOL improved, with significant improvements in the physical component of QOL.^[@bibr23-2054358119887154]^

Telehealth for CKD patients^[@bibr25-2054358119887154][@bibr26-2054358119887154]-[@bibr27-2054358119887154]^ showed benefits in travel time,^[@bibr25-2054358119887154]^ clinic attendance rates,^[@bibr27-2054358119887154]^ and QOL.^[@bibr25-2054358119887154]^ There was no change in burden of kidney disease^[@bibr25-2054358119887154]^ or a composite end point of doubling of serum creatinine, ESRD, and/or death.^[@bibr27-2054358119887154]^ Study duration ranged from 2 months^[@bibr25-2054358119887154]^ to 1 year.^[@bibr27-2054358119887154]^

Indigenous patients were evaluated with telehealth in only 1 study of satellite HD in New Zealand.^[@bibr28-2054358119887154]^ Providers and patients were satisfied with the satellite HD intervention, and there were improvements in physician travel time and costs.

Telehealth in HD units has been extensively studied;^[@bibr24-2054358119887154],[@bibr28-2054358119887154][@bibr30-2054358119887154][@bibr31-2054358119887154]-[@bibr32-2054358119887154]^ the most common model replaces physician visits to the satellite HD unit with a link in which an urban-based nephrology physician connects to the rural-based patient in a satellite HD unit.^[@bibr24-2054358119887154],[@bibr28-2054358119887154],[@bibr30-2054358119887154][@bibr31-2054358119887154]-[@bibr32-2054358119887154]^ Use of this model has high levels of provider and patient satisfaction,^[@bibr28-2054358119887154],[@bibr30-2054358119887154][@bibr31-2054358119887154]-[@bibr32-2054358119887154]^ with significant travel and cost savings for providers.^[@bibr28-2054358119887154]^ There were high rates of meeting standard benchmarks for laboratory investigations,^[@bibr24-2054358119887154],[@bibr32-2054358119887154]^ with lower hospitalization rates^[@bibr30-2054358119887154],[@bibr31-2054358119887154]^ and decreased health care-associated cost by US\$46 613 per annum.^[@bibr30-2054358119887154]^

An alternative model replaced patient visits to an urban HD facility for review by a nephrology team, with telehealth connection to a patient at his or her satellite HD unit.^[@bibr29-2054358119887154]^ This second model improved patient attendance rate while requiring 1 to 11 patients in the telehealth clinic to maintain cost neutrality.

Description of Outcomes: Satellite {#section34-2054358119887154}
----------------------------------

All satellite interventions evaluated the impact of a satellite HD unit on renal outcomes ([Appendix](#app1-2054358119887154){ref-type="app"} [Table A3](#table5-2054358119887154){ref-type="table"}).^[@bibr33-2054358119887154][@bibr34-2054358119887154][@bibr35-2054358119887154][@bibr36-2054358119887154][@bibr37-2054358119887154][@bibr38-2054358119887154][@bibr39-2054358119887154]-[@bibr40-2054358119887154]^ All studies described a satellite HD unit "spoke" as remote to the main central HD unit "hub," but closer to patients whose treatments were in the satellite facility. Studies that evaluated telehealth interventions in satellite HD units^[@bibr28-2054358119887154],[@bibr30-2054358119887154],[@bibr31-2054358119887154]^ are described in telehealth intervention, as the intervention in those studies was not the satellite clinic, but rather the telehealth system in the satellite clinic.

The study population included stable HD patients in all studies. However, 1 study evaluated outcomes not only in stable HD patients with acute medical issues but also dialysis-dependent AKI treated in a satellite HD clinic.^[@bibr37-2054358119887154]^ This intervention decreased transfer to the non-satellite HD facility, decreased travel time for families of patients with AKI requiring HD. Mortality was not compared with a pre-intervention program level; however, mortality of patients with AKI requiring HD was comparable with the published standards.

Satellite HD units show comparable mortality with the published controls when treating dialysis-dependent AKI.^[@bibr37-2054358119887154]^ On the contrary, satellite HD shows improved survival in rural satellite HD cohorts compared with urban HD units (odds ratio \[OR\] 0.77, *P* \< .0001) after correcting for multiple demographic and clinical factors. Hospitalization rates may be increased^[@bibr38-2054358119887154]^ or equivalent.^[@bibr40-2054358119887154]^

Hemodialysis clearance (dialysis clearance \[Kt/V\] or urea reduction ratio \[URR\]) was equivalent^[@bibr34-2054358119887154]^ or improved in satellite HD units.^[@bibr38-2054358119887154],[@bibr39-2054358119887154]^ There was no statistically significant difference between in-center and satellite HD patients when other laboratory investigations were studied (eg, hemoglobin, calcium, phosphate, albumin, parathyroid hormone \[PTH\], and HbA1C).^[@bibr33-2054358119887154],[@bibr34-2054358119887154],[@bibr39-2054358119887154]^ Patient QOL was equivalent^[@bibr34-2054358119887154],[@bibr38-2054358119887154]^ or improved.^[@bibr34-2054358119887154],[@bibr36-2054358119887154]^ Improvements in QOL occurred in the dialysis stress domain and in the cost and time associated with transportation to HD.^[@bibr34-2054358119887154],[@bibr37-2054358119887154]^

The cost associated with hospitalization appeared equivalent between satellite and in-center HD patients;^[@bibr38-2054358119887154]^ however, the total cost for satellite HD (median cost Can\$99 888/patient per year, range Can\$80 372-215 918) was higher.^[@bibr35-2054358119887154]^

Description of Outcomes: Other {#section35-2054358119887154}
------------------------------

Elsayed et al^[@bibr41-2054358119887154]^ offered stable CKD patients the choice between continuing standard nephrology follow-up, or a remote, community-based, disease management program created by a consultant nephrologist but implemented and followed by a rural family physician.^[@bibr41-2054358119887154]^ After 12 months, there was no difference in the laboratory values (mean eGFR, hemoglobin, calcium, and phosphate), but the cost for patients was dramatically reduced in the intervention arm, measured by annual carbon saving of 507 kg CO~2~ ([Appendix](#app1-2054358119887154){ref-type="app"} [Table A4](#table6-2054358119887154){ref-type="table"}).

Ayyalasomayaiula et al^[@bibr42-2054358119887154]^ used geographical information system, linked to a laboratory database, to identify locations for hypothetical new clinics that minimize travel time for rural patients with CKD.^[@bibr42-2054358119887154]^ The technique identified 4 ideal locations for CKD clinics that reduced the number of patients living more than 120 minutes away by 72.5%. When only 2 or 3 clinics were added, changing locations modified the number of patients living more than 120 minutes away by a large range, from 32 to 65%.

Villarba et al^[@bibr43-2054358119887154]^ evaluated an indigenous community without any dialysis facilities, whose members with ESRD either died or moved permanently outside their community to a non-indigenous community with dialysis facilities.^[@bibr43-2054358119887154]^ A remote home HD program was developed in cooperation with tribal elders, with strategies to address cultural and language challenges. Study participants reported improved comfort in their own community.

Discussion {#section36-2054358119887154}
==========

Chronic kidney disease affects indigenous and remote persons at a disproportionately high rate, with earlier onset and worse outcomes.^[@bibr2-2054358119887154][@bibr3-2054358119887154]-[@bibr4-2054358119887154],[@bibr7-2054358119887154],[@bibr8-2054358119887154]^ This is due to decreased access to health care and monitoring, long travel distances, multiple socioeconomic factors, and lack of a culturally safe health care infrastructure.^[@bibr6-2054358119887154][@bibr7-2054358119887154][@bibr8-2054358119887154][@bibr9-2054358119887154]-[@bibr10-2054358119887154]^ It is feasible to screen these populations to identify people who might benefit from kidney disease care,^[@bibr8-2054358119887154],[@bibr44-2054358119887154][@bibr45-2054358119887154]-[@bibr46-2054358119887154]^ but the optimal model to provide this care remains uncertain. This review identifies the best evidence for interventions to enhance renal outcomes in both indigenous and remote persons with kidney disease.

Studies showing positive outcomes in indigenous persons had a couple consistencies. First, successful programs were developed with authorities in the indigenous community. For example, Hoy et al^[@bibr16-2054358119887154]^ engaged the Tiwi Land Council and Tiwi Health Board to implement a community health workers clinic. Shephard et al^[@bibr8-2054358119887154]^ formed a partnership with the Umoona Tjutagku Health service to create a management program, named by the indigenous community "The Umoona Kidney Project." Villarba et al^[@bibr43-2054358119887154]^ worked with tribal elders to initiate a culturally safe home HD program.^[@bibr43-2054358119887154]^ Second, interventions were more successful when indigenous patients remained in their own community. This was facilitated by nephrologists,^[@bibr21-2054358119887154]^ nurse practitioners,^[@bibr12-2054358119887154],[@bibr20-2054358119887154]^ or a multidisciplinary team^[@bibr19-2054358119887154]^ going directly to the community. Alternatively, health workers were trained and remained in the indigenous community.^[@bibr8-2054358119887154],[@bibr13-2054358119887154][@bibr14-2054358119887154][@bibr15-2054358119887154]-[@bibr16-2054358119887154]^

All studies in indigenous persons were identified in Australia, New Zealand, or Canada. There were no studies from the United States, despite the high rates of ESRD in the American indigenous population.^[@bibr47-2054358119887154]^ There may be reasons for this geographic pattern of studies. First, the United States is more urbanized than Australia, New Zealand, or Canada.^[@bibr48-2054358119887154]^ This may decrease the populations available to study in rural or remote communities. Second, for a physician to use and bill for telehealth, patients must be in an approved originating site during the telehealth encounter.^[@bibr49-2054358119887154]^ These originating sites may be challenging to find in indigenous communities. On February 9, 2018, the Bipartisan Budget Act of 2018 was signed into law, which expanded originating sites.^[@bibr50-2054358119887154]^ More interventional studies are thus needed in multiple settings to enhance outcomes in this unique population.

Most studies performed in patients with non-dialysis-dependent CKD (11/16, 69%) were multidisciplinary interventions.^[@bibr8-2054358119887154],[@bibr12-2054358119887154][@bibr13-2054358119887154][@bibr14-2054358119887154][@bibr15-2054358119887154][@bibr16-2054358119887154][@bibr17-2054358119887154][@bibr18-2054358119887154][@bibr19-2054358119887154][@bibr20-2054358119887154][@bibr21-2054358119887154]-[@bibr22-2054358119887154]^ Despite the diversity of the components of the multidisciplinary intervention, clinical end points were consistently improved, including eGFR, ESRD, and mortality.^[@bibr16-2054358119887154],[@bibr17-2054358119887154],[@bibr20-2054358119887154]^ However, follow-up was greater than a year in only a few studies.^[@bibr8-2054358119887154],[@bibr15-2054358119887154],[@bibr17-2054358119887154]^ In the trial with the longest follow-up, handover of the study to community workers was followed by significant worsening of clinical outcomes, including death.^[@bibr15-2054358119887154]^ This highlights the importance of implementing and studying long-term sustainable interventions in remote populations, to assure that there is no decay of short-term benefits over the long-term. With increasing evidence for the use of sodium--glucose cotransporter-2 (SGLT-2) inhibitors, there is a continued need to assess the use of evidence-based interventions at a community and population level. The current studies analyzed begin to establish a body of evidence for active interventions in this area. The analysis of prescribing trends, when that data are available, would facilitate an understanding of the degree of knowledge translation to clinical practice across urban and rural communities.

All interventions in remote HD patients involved patients remaining in their community and the delivery of HD services either at^[@bibr28-2054358119887154],[@bibr43-2054358119887154]^ or close to their home.^[@bibr33-2054358119887154][@bibr34-2054358119887154][@bibr35-2054358119887154][@bibr36-2054358119887154][@bibr37-2054358119887154][@bibr38-2054358119887154][@bibr39-2054358119887154][@bibr40-2054358119887154]-[@bibr41-2054358119887154]^ The provision of HD in units closer to a patient's home associated with improved dialysis clearance,^[@bibr38-2054358119887154],[@bibr39-2054358119887154]^ QOL,^[@bibr33-2054358119887154],[@bibr36-2054358119887154],[@bibr38-2054358119887154]^ and survival.^[@bibr40-2054358119887154]^ However, the health care-associated costs of care may be higher than in-center HD, depending on the operating capacity of the satellite HD unit and transportation costs.^[@bibr35-2054358119887154]^ The prevalence of ESRD continues to expand worldwide,^[@bibr51-2054358119887154]^ increasing pressure on health care funders to provide patients access to renal replacement close to their home. Although clinical outcomes may be improved with satellite HD units over urban dialysis centers, PD-related or kidney transplantation-related outcomes are equivalent or superior to HD,^[@bibr52-2054358119887154],[@bibr53-2054358119887154]^ at a significantly lower cost.^[@bibr52-2054358119887154],[@bibr54-2054358119887154]^ Thus, growth of ESRD population in remote and indigenous centers might be better managed by expansion of PD and renal transplantation rather than satellite HD centers. Alternatively, if satellite HD units must be built, replacing nephrology team visits with telemedicine may reduce costs.^[@bibr30-2054358119887154]^

Only 1 study including PD patients was identified in this review. Krishna et al^[@bibr23-2054358119887154]^ performed QOL surveys in rural PD patients who had transitioned from in-person to telehealth appointments, showing reduced patient travel time and improved QOL with telemedicine.^[@bibr23-2054358119887154]^ On the contrary, there has been significant technological enhancements in the care of PD patients, with real-time remote monitoring of blood pressure and patient weight being incorporated via internet,^[@bibr55-2054358119887154],[@bibr56-2054358119887154]^ telephone,^[@bibr57-2054358119887154][@bibr58-2054358119887154][@bibr59-2054358119887154]-[@bibr60-2054358119887154]^ tablet,^[@bibr61-2054358119887154]^ or the PD machine itself.^[@bibr57-2054358119887154],[@bibr58-2054358119887154]^ Photographs or video can also be incorporated.^[@bibr61-2054358119887154]^ However, evidence for clinical benefit with newer technologies remains sparse.^[@bibr55-2054358119887154]^ Although these technologies hold a great deal of promise for remote and indigenous persons, more research is required before widespread use can be recommended.

This review has several strengths. First, it identifies characteristics of successful interventions to enhance renal outcomes in indigenous populations. Second, it identifies a range of evidence-based interventions in CKD, HD, and PD that enhance patients' outcomes in remote areas. Although meta-analysis of the data was not feasible due to the heterogeneity of trials, several important recommendations could be made. There were also important weaknesses. First, this review was limited to interventional trials that described clinical outcomes in renal disease. This limitation may have excluded studies that could improve the strength of the conclusions. On the contrary, we defined the study inclusion criteria to optimize the quality of the studies included. Second, the identified studies were limited to developed nations. However, this was also intentionally chosen a priori, so that recommendations could be generalizable to developed regions with remote and indigenous persons.

This review highlights the need for more research interventions in indigenous and remote communities with kidney disease, with long-term follow-up and measurement of clinical renal outcomes.
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  Multidisciplinary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------- ------------------------------------- ------------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Jiamjariyapon et al^[@bibr17-2054358119887154]^                                                                 Cluster randomized controlled trial   Thailand      CKD (no)    Community-based, multidisciplinary team with local community group, counseling, and home visits                                                                                eGFR, mortality, cardiac mortality, ESRD, 50% increase in creatinine, QOL, HbA1C, bicarbonate, Hb, BP, BMI, cholesterol, urine protein to creatinine ratio, 24-hour urinary sodium, mean number of medications (antihypertensives, insulin, statins, NSAIDs, diabetes)   Reduced composite end point of mortality, cardiac events, ESRD, and 50% increase in serum Cr from baseline. Biochemical markers (HbA1C, 24-hour urinary Na+, bicarbonate, triglyceride) also improved in intervention group. BP improved, no change in proteinuria
  Priyadarshana et al^[@bibr22-2054358119887154]^                                                                 Descriptive (observational)           Australia     CKD (no)    Change analysis and implementation of a rural outreach program to 22 communities                                                                                               Access to CKD services -- reduced travel and wait                                                                                                                                                                                                                        A telehealth service with referral coordination and performance indicators was developed. There were savings of more than A\$1.3 million on travel, reduction in waiting time from 6 months to 6 weeks
  Barrett et al^[@bibr12-2054358119887154]^                                                                       Cohort (prospective)                  Australia     CKD (yes)   NP led program to screen and implement management. Nephrologist by telehealth. Education for local community and clinicians                                                    Awareness of condition among patients and practitioners                                                                                                                                                                                                                  Overall perception of increased awareness of condition among patients and practitioners. 187 new patients with CKD identified
  Tan et al^[@bibr19-2054358119887154]^                                                                           Cohort (prospective)                  New Zealand   CKD (yes)   Primary care provider, NP and diabetes specialist titrate BP meds, facilitate adherence with home visits. Lifestyle/diet counseling provided in culturally appropriate care    Change in BP, eGFR, ACR remission: \>70% reduction. Secondary: A1c, non-fatal cardiovascular events, cerebrovascular and peripheral vascular events, ESRD, death                                                                                                         Improved BP with twice as many patients at target of \<125/85 and ACR with 28% of the patients in remission at the end of the study. No reported deaths in the study
  Walker et al^[@bibr20-2054358119887154]^                                                                        Cohort (prospective)                  New Zealand   CKD (yes)   NP systematic assessment and management of risk factors and titration of medications. Fortnightly visits × 12 weeks followed by monitoring to 12 months                        Primary: ACR. Secondary: eGFR, absolute cardiovascular risk. Multiple other measures (BP, A1c, BMI, etc)                                                                                                                                                                 Improvement in all markers. ACR (primary outcome) decreased by −6.75 mg/mmol/month. Good clinic staff satisfaction. Low patient dropout rate. Baseline patient population had suboptimal management initially
  Chalmers et al^[@bibr21-2054358119887154]^                                                                      Descriptive (observational)           Australia     CKD (yes)   Nephrologists traveling to remote clinics                                                                                                                                      Access to nephrology care                                                                                                                                                                                                                                                Reduced travel time for patients. Presumed but not calculated cost savings
  Hotu et al^[@bibr13-2054358119887154]^                                                                          Randomized, controlled, study         Australia     CKD (yes)   Nurse-led, local health care assistant monthly visit vs usual care. MD-guided medication adjustment. Transportation of patient to pharmacy and lab (for blood work) offered.   Primary: change in BP. Secondary: 24-hour urine protein, HbA1c, total cholesterol, echo parameters, medication compliance                                                                                                                                                Improved BP control (SBP 149 vs 140 at 12 months for intervention vs control), more antihypertensives prescribed, decreased proteinuria
  Senior et al^[@bibr18-2054358119887154]^                                                                        Cohort (prospective)                  Canada        CKD (yes)   RN and RD led clinics focused on cardiovascular and renal risk factors                                                                                                         Patient summary of Diabetes Self Care, Clinic staff satisfaction, community practitioners satisfaction, clinical measures: BP, A1c, ACR, lipids                                                                                                                          Good satisfaction among staff and practitioner participants. Targets harder to attain with higher CKD stage. Long-term outcomes/follow-up and cost-effectiveness unknown
  Shephard et al^[@bibr8-2054358119887154]^                                                                       Cohort (prospective)                  Australia     CKD (yes)   Management program with ACE-inhibitor initiation/titration                                                                                                                     Point of care ACR, BP                                                                                                                                                                                                                                                    72% compliance with ACE inhibitor treatment. Improved BP (SBP lying 151 ±3 to 137 ± 3, similar statistically significant change for diastolic). Patients expressed concern about renal disease, and satisfaction with care team
  Hoy, Kondalsamy-Cjenakesavan, Scheppingen, et al^[@bibr14-2054358119887154]^                                    Cohort (prospective)                  Australia     CKD (yes)   Local health workers with remote physician support, doing regular testing for chronic disease and risk factors with treatment                                                  Risk factor diagnosis (HTN, DM, BMI), treatment initiation (DM, ACEi), implementation challenges review                                                                                                                                                                  Found diabetes as a late factor in chronic disease onset suggesting more upstream interventions (HTN, BMI) needed. Treatment titration affected by poor staffing and absenteeism, but still showed improved BP
  Hoy et al^[@bibr16-2054358119887154]^ and Hoy, Kondalsamy-Cjenakesavan, and Nicol^[@bibr15-2054358119887154]^   Cohort (prospective)                  Australia     CKD (yes)   Community health workers' clinic, with systematic titration of meds for BP, CKD control and lifestyle counseling. Long-term follow-up with interim handover to community       Change in BP, ACR, GFR, creatinine, renal and non-renal deaths                                                                                                                                                                                                           Early: improved BP, 50% reduced death, 57% reduced renal death, no change in urine ACR. Benefit took 2 years to appear. LATE: 3 years after study start (study handover to community), increased BP, overall and renal death rates

*Note.* ACE = angiotensin-converting enzyme; ACEi = angiotensin-converting enzyme inhibitor; ACR = albumin--creatinine ratio; BMI = body mass index; BP = blood pressure; CKD = chronic kidney disease; DM = diabetes mellitus; ESRD = end-stage renal disease; eGFR = estimated glomerular filtration rate; HD = hemodialysis; HTN = hypertension; PD = peritoneal dialysis; QOL = quality of life; NP = nurse practitioner; MD = medical doctor; RN = registered nurse; SBP = systolic blood pressure.
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  Telehealth                                                                                                                                                                                                                                                                                                                                                                                              
  ------------------------------------------------ ----------------------------- ------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Al Azab and Khader^[@bibr25-2054358119887154]^   Cohort (prospective)          Jordan        CKD (no)                        Patients referred to telenephrology clinics                                                                                    Patient satisfaction, visit characteristics                                                                                                 Improved travel time, cost, ease of access, and QOL. No improvement on burden of kidney disease scale
  Krishna et al^[@bibr23-2054358119887154]^        Descriptive (survey)          USA           PD (no)                         Care for PD patients living in rural areas was initiated with in-person appointments and transitioned to telemedicine visits   Quality of life questionnaires, travel time saved                                                                                           Improved physical score on QOL questionnaire, improved Illness Intrusiveness Ratings Scale. Significant patient travel time saved (\~2 hours) for each telemedicine appointment
  Pichler et al^[@bibr26-2054358119887154]^        Descriptive (survey)          USA           CKD (no)                        Provider-to-provider telemedicine consultation service for Veterans Affairs practitioners                                      Provider satisfaction                                                                                                                       Providers satisfied with the program, endorsed improved knowledge, coordination of care, and felt consultations improved quality of care and job satisfaction
  Kapojos et al^[@bibr29-2054358119887154]^        Descriptive (observational)   Australia     HD (unknown)                    Remote telehealth clinics versus HD unit appointments                                                                          Attendance rate in clinics and cost analysis                                                                                                Improved attendance in telehealth clinics. Identified 1 to 11 patients needed in telehealth clinic to remain cost neutral
  Rohatgi et al^[@bibr27-2054358119887154]^        Cohort (retrospective)        USA           CKD (no)                        Telenephrology clinics                                                                                                         No-show rate for rural patients. Composite end point (doubling Cr, ESRD, and/or death)                                                      Decreased no-show rate. No difference in composite end point
  Tan et al^[@bibr28-2054358119887154]^            Descriptive (observational)   New Zealand   HD (yes)                        Telemedicine in satellite HD                                                                                                   Provider and patient satisfaction, physician travel time, and costs                                                                         Providers and patients satisfied with the service. Significant travel and cost savings for physicians
  Sicotte et al^[@bibr24-2054358119887154]^        Cohort (prospective)          Canada        HD (no)                         Telemedicine in HD                                                                                                             Clinical outcomes (based on National Kidney Foundation benchmarks), health care utilization                                                 No significant difference in clinical markers from initiation of teledialysis, NKF benchmarks met pre and post. Decrease in medication changes with teledialysis. No change in HD sessions or transfers to tertiary centers
  Whitten and Buis^[@bibr32-2054358119887154]^     Cohort (cross-sectional)      USA           HD (no)                         Telemedicine in HD                                                                                                             Patient and provider satisfaction, Hb, URR, albumin, Pi, Ca                                                                                 Providers and patients had positive perceptions. No clear patient preference for telemedicine. All Renal Network 11 biochemistry targets met but Ca
  Stanescu et al^[@bibr31-2054358119887154]^       Cohort (prospective)          France        Elderly (mean age 76) HD (no)   Telemedicine in satellite HD                                                                                                   Dialysis parameters (Kt/V, weight change). Blood pressure control, hospitalization, fistula thrombosis, patient and provider satisfaction   Fewer hospitalizations, both patients and nurses satisfied with the program
  Rumpsfeld et al^[@bibr30-2054358119887154]^      Descriptive (observational)   Norway        HD (no)                         Telemedicine in satellite HD                                                                                                   Cost-effectiveness, hospital visits, physician visits, nurse satisfaction                                                                   US\$46 613 saved per annum, decreased hospitalization, decreased physician visits, maintained nursing satisfaction

*Note.* Cr = creatinine; CKD = chronic kidney disease; ESRD = end-stage renal disease; HD = hemodialysis; PD = peritoneal dialysis; QOL = quality of life; NKF = national kidney foundation; URR = urea reduction ratio.
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  Satellite clinics                                                                                                                                                                                                                       
  ------------------------------------------------- ----------------------------- -------- ------------------- -------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Rees et al^[@bibr37-2054358119887154]^            Descriptive (observational)   UK       HD, acute HD (no)   Satellite HD units   Distance traveled by patient and patient's relatives, mortality of dialysis-dependent AKI             Decreased travel time for patients and their relatives, mortality comparable with published cohorts
  Ferguson et al^[@bibr35-2054358119887154]^        Cost-effectiveness            Canada   HD (no)             Satellite HD units   Median cost per patient                                                                               Cost (median = Can\$99 888) may be higher depending on operating capacity and transportation costs
  Zacharias et al^[@bibr40-2054358119887154]^       Cohort (prospective)          Canada   HD (no)             Satellite HD units   Family physician access, hospitalization, death                                                       Improved survival (OR 0.77, 95% CI 0.68-0.88, *P* \< .0001), more likely to access a family physician
  Organ and MacDonald^[@bibr36-2054358119887154]^   Descriptive (survey)          Canada   HD (no)             Satellite HD unit    Patient QOL                                                                                           Improved QOL
  Diamant et al^[@bibr34-2054358119887154]^         Cohort (cross-sectional)      Canada   HD (no)             Satellite HD units   Albumin, Hb, Ca-P, AVF function, Kt/V, patient QOL                                                    More likely to attain albumin, Hb and Ca-P targets. No change in QOL
  Diamant et al^[@bibr33-2054358119887154]^         Descriptive (survey)          Canada   HD (no)             Satellite HD units   Patient QOL, patient travel time and cost, albumin, Hb, URR, Kt/V, ferritin, transferrin saturation   Higher physical functioning score on QOL survey, lower travel time and cost, higher perceived QOL
  Vasilevsky et al^[@bibr39-2054358119887154]^      Cohort (retrospective)        Canada   HD (no)             Satellite HD units   Kt/V, BP, Hb, albumin, Pi, PTH, transfers to urban center                                             Improved Kt/V (statistically but not clinically significant)
  Roderick et al^[@bibr38-2054358119887154]^        Descriptive (survey)          UK       HD (no)             Satellite HD units   Kt/V, patient QOL, program cost                                                                       Improved URR and QOL (patient satisfaction), cost uncertain

*Note.* AKI = acute kidney injury; BP = blood pressure; CKD = chronic kidney disease; HD = hemodialysis; PD = peritoneal dialysis; PTH = parathyroid hormone; QOL = quality of life; AVF = arteriovenous fistula; URR = urea reduction ratio; PTH = parathyroid hormone.
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  Elsayed et al^[@bibr41-2054358119887154]^            Cohort (prospective)   UK          CKD (no)   Remote disease management program with family practitioner and telephone follow-up with nurse specialist   eGFR, Hb, Ca, Pi, Cost                No difference compared with those who continued standard care
  Ayyalasomayajula et al^[@bibr42-2054358119887154]^   Other                  Canada      CKD (no)   GIS analysis of patient location                                                                           Clinic travel time                    Reduction in number of patients living \>120 minutes from clinic by 72.5%, increase patients living \<30 minutes away by 520 (2.2%)
  Villarba et al^[@bibr43-2054358119887154]^           Descriptive (survey)   Australia   HD (yes)   Home HD program                                                                                            Patient satisfaction and compliance   Improved comfort in own community. High rates of compliance and improved self-care with initiation of home HD

*Note.* CKD = chronic kidney disease; HD = hemodialysis; PD = peritoneal dialysis; GIS = geographical information system.
